International union of basic and clinical pharmacology. XC. Multisite pharmacology: Recommendations for the nomenclature of receptor allosterism and allosteric ligands

Pharmacological Reviews

Volumn 66, Issue 4, 2014, Pages 918-947

  Christopoulos, Arthur ^a   Changeux, Jean Pierre ^b   Catterall, William A ^c   Fabbro, Doriano ^d   Burris, Thomas P ^e   Cidlowski, John A ^f   Olsen, Richard W ^g   Peters, John A ^h   Neubig, Richard R ⁱ   Pin, Jean Philippe ^j   Sexton, Patrick M ^a   Kenakin, Terry P ^k   Ehlert, Frederick J ^l   Spedding, Michael ^m   Langmead, Christopher J ^a  

^a MONASH UNIVERSITY   (Australia)

^b INSTITUT PASTEUR   (France)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Piqur Therapeutics AG   (Switzerland)

^e SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF DUNDEE   (United Kingdom)

ⁱ MICHIGAN STATE UNIVERSITY   (United States)

^j INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^k UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m Nanobacterie SARL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; G PROTEIN COUPLED RECEPTOR; ION CHANNEL; LIGAND; PROTEIN TYROSINE KINASE;

ALLOSTERISM; CHEMICAL MODEL; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; NOMENCLATURE;

ALLOSTERIC REGULATION; HUMANS; ION CHANNELS; LIGANDS; MODELS, CHEMICAL; PROTEIN-TYROSINE KINASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; TERMINOLOGY AS TOPIC;

EID: 84904301809     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.114.008862     Document Type: Article

References (302)

1. Acker TM, Yuan H, Hansen KB, Vance KM, Ogden KK, Jensen HS, Burger PB, Mullasseril P, Snyder JP, and Liotta DC, et al. (2011) Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunitselective modulators. Mol Pharmacol 80:782-795.
2. Adrián FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, and Manley P, et al. (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2:95-102.
3. Albanell J, Codony J, Rovira A, Mellado B, and Gascón P (2003) Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 532:253-268.
4. Allegretti M, Bertini R, Bizzarri C, Beccari A, Mantovani A, and Locati M (2008) Allosteric inhibitors of chemoattractant receptors: opportunities and pitfalls. Trends Pharmacol Sci 29:280-286.
5. Antony J, Kellershohn K, Mohr-Andrä M, Kebig A, Prilla S, Muth M, Heller E, Disingrini T, Dallanoce C, and Bertoni S, et al. (2009) Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J 23:442-450.
6. Arkhipov A, Shan Y, Das R, Endres NF, Eastwood MP, Wemmer DE, Kuriyan J, and Shaw DE (2013) Architecture and membrane interactions of the EGF receptor. Cell 152:557-569.
7. Armstrong CM(1974) Ionic pores, gates, and gating currents. Q Rev Biophys 7:179-210.
8. Armstrong CM (1981) Sodium channels and gating currents. Physiol Rev 61:644-683.
9. Arnold LA, Estébanez-Perpiñá E, Togashi M, Jouravel N, Shelat A, McReynolds AC, Mar E, Nguyen P, Baxter JD, and Fletterick RJ, et al. (2005) Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. J Biol Chem 280:43048-43055.
10. Arnold LA, Kosinski A, Estébanez-Perpiñá E, Fletterick RJ, and Guy RK (2007) Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem 50:5269-5280.
11. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br Pharmacol Chemother 14:48-58.
12. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Markowitz S, Willson JK, Parmigiani G, and Kinzler KW, et al. (2003) Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300:949.
13. Barnard EA, Skolnick P, Olsen RW, Mohler H, Sieghart W, Biggio G, Braestrup C, Bateson AN, and Langer SZ (1998) International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 50:291-313.
14. Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, Jones RE, Kahana JA, Kral AM, Leander K, and Lee LL, et al. (2005) Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 385:399-408.
15. Bautista DM, Siemens J, Glazer JM, Tsuruda PR, Basbaum AI, Stucky CL, Jordt SE, and Julius D (2007) The menthol receptor TRPM8 is the principal detector of environmental cold. Nature 448:204-208.
16. Bertrand D and Gopalakrishnan M (2007) Allosteric modulation of nicotinic acetylcholine receptors. Biochem Pharmacol 74:1155-1163.
17. Black J (1989) Drugs from emasculated hormones: the principle of syntopic antagonism. Science 245:486-493.
18. Black JW, Gerskowitch VP, Leff P, and Shankley NP (1986) Analysis of competitive antagonism when this property occurs as part of a pharmacological resultant. Br J Pharmacol 89:547-555.
19. Bocquet N, Nury H, Baaden M, Le Poupon C, Changeux JP, Delarue M, and Corringer PJ (2009) X-ray structure of a pentameric ligand-gated ion channel in an apparently open conformation. Nature 457:111-114.
20. Bono F, De Smet F, Herbert C, De Bock K, Georgiadou M, Fons P, Tjwa M, Alcouffe C, Ny A, and Bianciotto M, et al. (2013) Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell 23:477-488.
21. Bourinet E, Soong TW, Sutton K, Slaymaker S, Mathews E, Monteil A, Zamponi GW, Nargeot J, and Snutch TP (1999) Splicing of alpha 1A subunit gene generates phenotypic variants of P-and Q-type calcium channels. Nat Neurosci 2:407-415.
22. Bruning JB, Parent AA, Gil G, Zhao M, Nowak J, Pace MC, Smith CL, Afonine PV, Adams PD, and Katzenellenbogen JA, et al. (2010) Coupling of receptor conformation and ligand orientation determine graded activity. Nat Chem Biol 6: 837-843.
23. Bruns RF and Fergus JH (1990) Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol 38:939-949.
24. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engström O, Ohman L, Greene GL, Gustafsson JA, and Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758.
25. Burris TP, Solt LA, Wang Y, Crumbley C, Banerjee S, Griffett K, Lundasen T, Hughes T, and Kojetin DJ (2013) Nuclear receptors and their selective pharmacologic modulators. Pharmacol Rev 65:710-778.
26. Canals M, Lane JR, Wen A, Scammells PJ, Sexton PM, and Christopoulos A (2012) A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation. J Biol Chem 287:650-659.
27. Canals M, Sexton PM, and Christopoulos A (2011) Allostery in GPCRs: 'MWC' revisited. Trends Biochem Sci 36:663-672.
28. Cao E, Liao M, Cheng Y, and Julius D (2013) TRPV1 structures in distinct conformations reveal activation mechanisms. Nature 504:113-118.
29. Catterall WA (1980) Neurotoxins that act on voltage-sensitive sodium channels in excitable membranes. Annu Rev Pharmacol Toxicol 20:15-43.
30. Catterall WA (2010) Ion channel voltage sensors: structure, function, and pathophysiology. Neuron 67:915-928.
31. Catterall WA, Cestèle S, Yarov-Yarovoy V, Yu FH, Konoki K, and Scheuer T (2007) Voltage-gated ion channels and gating modifier toxins. Toxicon 49:124-141.
32. Catterall WA, Goldin AL, and Waxman SG (2005a) International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltagegated sodium channels. Pharmacol Rev 57:397-409.
33. Catterall WA, Perez-Reyes E, Snutch TP, and Striessnig J (2005b) International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 57:411-425.
34. Cazorla M, Jouvenceau A, Rose C, Guilloux JP, Pilon C, Dranovsky A, and Prémont J (2010) Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice. PLoS ONE 5:e9777.
35. Cestèle S and Catterall WA (2000) Molecular mechanisms of neurotoxin action on voltage-gated sodium channels. Biochimie 82:883-892.
36. Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christopoulos A, Lazareno S, Birdsall NJ, and Bymaster FP, et al. (2008) Allosteric modulation of the muscarinicM4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci USA 105:10978-10983.
37. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, and Rastinejad F (2008) Structure of the intact PPAR-gamma-RXR-nuclear receptor complex on DNA. Nature 456:350-356.
38. Chandra V, Huang P, Potluri N, Wu D, Kim Y, and Rastinejad F (2013) Multidomain integration in the structure of the HNF-4a nuclear receptor complex. Nature 495: 394-398.
39. Chang CY, Norris JD, Grøn H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, and McDonnell DP (1999) Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. Mol Cell Biol 19:8226-8239.
40. Chang CY, Abdo J, Hartney T, and McDonnell DP (2005) Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. Mol Endocrinol 19:2478-2490.
41. Changeux JP (1961) The feedback control mechanisms of biosynthetic L-threonine deaminase by L-isoleucine. Cold Spring Harb Symp Quant Biol 26:313-318.
42. Changeux JP (2010) Allosteric receptors: from electric organ to cognition. Annu Rev Pharmacol Toxicol 50:1-38.
43. Changeux JP (2012) Allostery and the Monod-Wyman-Changeux model after 50 years. Annu Rev Biophys 41:103-133.
44. Changeux JP (2013a) 50 years of allosteric interactions: the twists and turns of the models. Nat Rev Mol Cell Biol 14:819-829.
45. Changeux JP (2013b) The concept of allosteric modulation: an overview. Drug Discov Today Technol 10:e223-e228.
46. Changeux JP and Edelstein SJ (1998) Allosteric receptors after 30 years. Neuron 21: 959-980.
47. Changeux JP and Edelstein SJ (2005) Allosteric mechanisms of signal transduction. Science 308:1424-1428.
48. Changeux JP, Thiéry J, Tung Y, and Kittel C (1967) On the cooperativity of biological membranes. Proc Natl Acad Sci USA 57:335-341.
49. Chen J and Hage DS (2004) Quantitative analysis of allosteric drug-protein binding by biointeraction chromatography. Nat Biotechnol 22:1445-1448.
50. Chiara DC, Jayakar SS, Zhou X, Zhang X, Savechenkov PY, Bruzik KS, Miller KW, and Cohen JB (2013) Specificity of intersubunit general anesthetic-binding sites in the transmembrane domain of the human a1b3g2 g-aminobutyric acid type A (GABAA) receptor. J Biol Chem 288:19343-19357.
51. Chiara DC, Gill JF, Chen Q, Tillman T, Dailey WP, Eckenhoff RG, Xu Y, Tang P, and Cohen JB (2014) Photoaffinity labeling the propofol binding site in GLIC. Biochemistry 53:135-142.
52. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, and Leahy DJ (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756-760.
53. Choi J, Chen J, Schreiber SL, and Clardy J (1996) Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273:239-242.
54. Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1:198-210.
55. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
56. Clark AL and Mitchelson F (1976) The inhibitory effect of gallamine on muscarinic receptors. Br J Pharmacol 58:323-331.
57. Collingridge GL, Olsen R, Peters JA, and Spedding M (2009) Ligand gated ion channels. Neuropharmacology 56:1.
58. Colquhoun D (1973) The relation between classical and cooperative models for drug action, in Drug Receptors (Rang HP ed) pp 149-182, Macmillan Press, London.
59. Colquhoun D (1998) Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 125:924-947.
60. Colquhoun D (2007) Why the Schild method is better than Schild realised. Trends Pharmacol Sci 28:608-614.
61. Colquhoun D and Lape R (2012) Perspectives on: conformational coupling in ion channels: allosteric coupling in ligand-gated ion channels. J Gen Physiol 140: 599-612.
62. Conigrave AD, Quinn SJ, and Brown EM (2000) L-amino acid sensing by the extracellular Ca2+-sensing receptor. Proc Natl Acad Sci USA 97:4814-4819.
63. Conn PJ, Christopoulos A, and Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8:41-54.
64. Converso A, Hartingh T, Garbaccio RM, Tasber E, Rickert K, Fraley ME, Yan Y, Kreatsoulas C, Stirdivant S, and Drakas B, et al. (2009) Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. Bioorg Med Chem Lett 19: 1240-1244.
65. Corringer PJ, Poitevin F, Prevost MS, Sauguet L, Delarue M, and Changeux JP (2012) Structure and pharmacology of pentameric receptor channels: from bacteria to brain. Structure 20:941-956.
66. Costa T and Herz A (1989) Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86:7321-7325.
67. Cowan-Jacob SW (2006) Structural biology of protein tyrosine kinases. Cell Mol Life Sci 63:2608-2625.
68. Cuatrecasas P (1974) Membrane receptors. Annu Rev Biochem 43:169-214.
69. Cui Q and Karplus M (2008) Allostery and cooperativity revisited. Protein Sci 17: 1295-1307.
70. daCosta CJ, Medaglia SA, Lavigne N, Wang S, Carswell CL, and Baenziger JE (2009) Anionic lipids allosterically modulate multiple nicotinic acetylcholine receptor conformational equilibria. J Biol Chem 284:33841-33849.
71. de Kruijf P, Lim HD, Roumen L, Renjaän VA, Zhao J, Webb ML, Auld DS, Wijkmans JC, Zaman GJ, and Smit MJ, et al. (2011) Identification of a novel allosteric binding site in the CXCR2 chemokine receptor. Mol Pharmacol 80:1108-1118.
72. Del Castillo J and Katz B (1957) Interaction at end-plate receptors between different choline derivatives. Proc R Soc Lond B Biol Sci 146:369-381.
73. De Lean A, Stadel JM, and Lefkowitz RJ (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled betaadrenergic receptor. J Biol Chem 255:7108-7117.
74. Dong M, Cox RF, and Miller LJ (2009) Juxtamembranous region of the amino terminus of the family B G protein-coupled calcitonin receptor plays a critical role in small-molecule agonist action. J Biol Chem 284:21839-21847.
75. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, and Napier C, et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49:4721-4732.
76. Downing SS, Lee YT, Farb DH, and Gibbs TT (2005) Benzodiazepine modulation of partial agonist efficacy and spontaneously active GABA(A) receptors supports an allosteric model of modulation. Br J Pharmacol 145:894-906.
77. Dror RO, Green HF, Valant C, Borhani DW, Valcourt JR, Pan AC, Arlow DH, Canals M, Lane JR, and Rahmani R, et al. (2013) Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature 503:295-299.
78. Ehlert FJ (1985) The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. Mol Pharmacol 28:410-421.
79. Ehlert FJ (1988) Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33:187-194.
80. Ehlert FJ (2005) Analysis of allosterism in functional assays. J Pharmacol Exp Ther 315:740-754.
81. Estébanez-Perpiñá E, Arnold LA, Jouravel N, Togashi M, Blethrow J, Mar E, Nguyen P, Phillips KJ, Baxter JD, and Webb P, et al. (2007a) Structural insight into the mode of action of a direct inhibitor of coregulator binding to the thyroid hormone receptor. Mol Endocrinol 21:2919-2928.
82. Estébanez-Perpiñá E, Arnold LA, Nguyen P, Rodrigues ED, Mar E, Bateman R, Pallai P, Shokat KM, Baxter JD, and Guy RK, et al. (2007b) A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci USA 104:16074-16079.
83. Fabbro D, Cowan-Jacob SW, Möbitz H, and Martiny-Baron G (2012) Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol Biol 795:1-34.
84. Fabbro D and García-Echeverría C (2002) Targeting protein kinases in cancer therapy. Curr Opin Drug Discov Devel 5:701-712.
85. Fabbro D, Manley PW, Jahnke W, Liebetanz J, Szyttenholm A, Fendrich G, Strauss A, Zhang J, Gray NS, and Adrian F, et al. (2010) Inhibitors of the Abl kinase directed at either the ATP-or myristate-binding site. Biochim Biophys Acta 1804: 454-462.
86. Fenalti G, Giguere PM, Katritch V, Huang XP, Thompson AA, Cherezov V, Roth BL, and Stevens RC (2014) Molecular control of d-opioid receptor signalling. Nature 506:191-196.
87. Fenton AW (2008) Allostery: an illustrated definition for the 'second secret of life'. Trends Biochem Sci 33:420-425.
88. Ferry DR and Glossmann H (1982) Evidence of multiple receptor sites within the putative calcium channel. Naunyn Schmiedebergs Arch Pharmacol 321:80-83.
89. Fleishman SJ, Schlessinger J, and Ben-Tal N (2002) A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci USA 99: 15937-15940.
90. Flynn GE, Black KD, Islas LD, Sankaran B, and Zagotta WN (2007) Structure and rearrangements in the carboxy-terminal region of SpIH channels. Structure 15: 671-682.
91. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, and Müller CE (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 63:1-34.
92. Galande AK, Bramlett KS, Trent JO, Burris TP, Wittliff JL, and Spatola AF (2005) Potent inhibitors of LXXLL-based protein-protein interactions. ChemBioChem 6: 1991-1998.
93. Galzi JL, Bertrand S, Corringer PJ, Changeux JP, and Bertrand D (1996) Identification of calcium binding sites that regulate potentiation of a neuronal nicotinic acetylcholine receptor. EMBO J 15:5824-5832.
94. Galzi JL and Changeux JP (1994) Neurotransmitter-gated ion channels as unconventional allosteric proteins. Curr Opin Struct Biol 4:554-565.
95. Gao F, Sexton PM, Christopoulos A, and Miller LJ (2008) Benzodiazepine ligands can act as allosteric modulators of the Type 1 cholecystokinin receptor. Bioorg Med Chem Lett 18:4401-4404.
96. Geistlinger TR, McReynolds AC, and Guy RK (2004) Ligand-selective inhibition of the interaction of steroid receptor coactivators and estrogen receptor isoforms. Chem Biol 11:273-281.
97. Gerhart JC and Pardee AB (1962) The enzymology of control by feedback inhibition. J Biol Chem 237:891-896.
98. Gill JK, Savolainen M, Young GT, Zwart R, Sher E, and Millar NS (2011) Agonist activation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci USA 108:5867-5872.
99. Gilman AG (1987) G proteins: transducers of receptor-generated signals. Annu Rev Biochem 56:615-649.
100. Grimm C, Aneiros E, and de Groot M (2011) Dissecting TRPV1: lessons to be learned? Channels (Austin) 5:201-204.
101. Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, and Mahaney PE, et al. (2003) Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301:370-373.
102. Guertin KR and Grimsby J (2006) Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy. Curr Med Chem 13:1839-1843.
103. Hall DA (2000) Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol Pharmacol 58:1412-1423.
104. Hall JM, Chang CY, and McDonnell DP (2000) Development of peptide antagonists that target estrogen receptor beta-coactivator interactions. Mol Endocrinol 14: 2010-2023.
105. Hamm HE (1998) The many faces of G protein signaling. J Biol Chem 273:669-672.
106. Hamouda AK, Kimm T, and Cohen JB (2013) Physostigmine and galanthamine bind in the presence of agonist at the canonical and noncanonical subunit interfaces of a nicotinic acetylcholine receptor. J Neurosci 33:485-494.
107. Hanchar HJ, Chutsrinopkun P, Meera P, Supavilai P, Sieghart W, Wallner M, and Olsen RW (2006) Ethanol potently and competitively inhibits binding of the alcohol antagonist Ro15-4513 to alpha4/6beta3delta GABAA receptors. Proc Natl Acad Sci USA 103:8546-8551.
108. Hansen SB and Taylor P (2007) Galanthamine and non-competitive inhibitor binding to ACh-binding protein: evidence for a binding site on non-alpha-subunit interfaces of heteromeric neuronal nicotinic receptors. J Mol Biol 369:895-901.
109. Hansen KB and Traynelis SF (2011) Structural and mechanistic determinants of a novel site for noncompetitive inhibition of GluN2D-containing NMDA receptors. J Neurosci 31:3650-3661.
110. Hansen KB, Ogden KK, and Traynelis SF (2012) Subunit-selective allosteric inhibition of glycine binding to NMDA receptors. J Neurosci 32:6197-6208.
111. Hardy JA and Wells JA (2004) Searching for new allosteric sites in enzymes. Curr Opin Struct Biol 14:706-715.
112. Heery DM, Kalkhoven E, Hoare S, and Parker MG (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387: 733-736.
113. Herbert C, Schieborr U, Saxena K, Juraszek J, De Smet F, Alcouffe C, Bianciotto M, Saladino G, Sibrac D, and Kudlinzki D, et al. (2013) Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling. Cancer Cell 23:489-501.
114. Hess P, Lansman JB, and Tsien RW (1984) Different modes of Ca channel gating behaviour favoured by dihydropyridine Ca agonists and antagonists. Nature 311: 538-544.
115. Hibbs RE and Gouaux E (2011) Principles of activation and permeation in an anionselective Cys-loop receptor. Nature 474:54-60.
116. Hille B (2001) Ionic channels of excitable membranes, Sinauer Associates Inc., Sunderland, MA. Hindie V, Stroba A, Zhang H, Lopez-Garcia LA, Idrissova L, Zeuzem S, Hirschberg D,
117. Sunderland, MA. Hindie V, Stroba A, Zhang H, Lopez-Garcia LA, Idrissova L, Zeuzem S, Hirschberg D, Schaeffer F, Jørgensen TJ, and Engel M, et al. (2009) Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. Nat Chem Biol 5:758-764.
118. Hoare SR, Fleck BA, Gross RS, Crowe PD, Williams JP, and Grigoriadis DE (2008) Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation. Mol Pharmacol 73:1371-1380.
119. Hockerman GH, Johnson BD, Abbott MR, Scheuer T, and Catterall WA (1997a) Molecular determinants of high affinity phenylalkylamine block of L-type calcium channels in transmembrane segment IIIS6 and the pore region of the alpha1 subunit. J Biol Chem 272:18759-18765.
120. Hockerman GH, Peterson BZ, Sharp E, Tanada TN, Scheuer T, and Catterall WA (1997b) Construction of a high-affinity receptor site for dihydropyridine agonists and antagonists by single amino acid substitutions in a non-L-type Ca2+ channel. Proc Natl Acad Sci USA 94:14906-14911.
121. Hogg RC, Buisson B, and Bertrand D (2005) Allosteric modulation of ligand-gated ion channels. Biochem Pharmacol 70:1267-1276.
122. Hollenstein K, Kean J, Bortolato A, Cheng RK, Doré AS, Jazayeri A, Cooke RM, Weir M, and Marshall FH (2013) Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499:438-443.
123. Hsieh AC and Moasser MM (2007) Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 97:453-457.
124. Hubbard SR (1997) Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 16:5572-5581.
125. Hughes TS, Giri PK, de Vera IM, Marciano DP, Kuruvilla DS, Shin Y, Blayo AL, Kamenecka TM, Burris TP, and Griffin PR, et al. (2014) An alternate binding site for PPARg ligands. Nat Commun 5:3571 DOI: 10.1038/ncomms4571.
126. Hynes NE and Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354.
127. Inoki K, Corradetti MN, and Guan KL (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37:19-24.
128. Issafras H, Corbin JA, Goldfine ID, and Roell MK (2014) Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1b antibody with differential receptor-modulating properties. J Pharmacol Exp Ther 348:202-215.
129. Ito H, Klugbauer N, and Hofmann F (1997) Transfer of the high affinity dihydropyridine sensitivity from L-type To non-L-type calcium channel. Mol Pharmacol 52:735-740.
130. Jackson MB (1984) Spontaneous openings of the acetylcholine receptor channel. Proc Natl Acad Sci USA 81:3901-3904.
131. Jacobson KA and Gao ZG (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5:247-264.
132. Janis RA, Sarmiento JG, Maurer SC, Bolger GT, and Triggle DJ (1984) Characteristics of the binding of [3H]nitrendipine to rabbit ventricular membranes: modification by other Ca++ channel antagonists and by the Ca++ channel agonist Bay K 8644. J Pharmacol Exp Ther 231:8-15.
133. Jenkinson DH, Barnard EA, Hoyer D, Humphrey PP, Leff P, and Shankley NP (1995) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on terms and symbols in quantitative pharmacology. Pharmacol Rev 47:255-266.
134. Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, and Kuriyan J (2011) Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell 42:9-22.
135. Karlin A (1967) On the application of "a plausible model" of allosteric proteins to the receptor for acetylcholine. J Theor Biol 16:306-320.
136. Katz B and Thesleff S (1957) A study of the desensitization produced by acetylcholine at the motor end-plate. J Physiol 138:63-80.
137. Kenakin T (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4:919-927.
138. Kenakin T (2009) Interrogating 7TM receptors: does texture in the question yield greater texture in the answer? J Recept Signal Transduct Res 29:132-139.
139. Kenakin T and Christopoulos A (2013) Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12:205-216.
140. Kenakin T and Miller LJ (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62:265-304.
141. Keov P, Sexton PM, and Christopoulos A (2011) Allosteric modulation of G proteincoupled receptors: a pharmacological perspective. Neuropharmacology 60:24-35.
142. Kern D and Zuiderweg ER (2003) The role of dynamics in allosteric regulation. Curr Opin Struct Biol 13:748-757.
143. Kjelsberg MA, Cotecchia S, Ostrowski J, Caron MG, and Lefkowitz RJ (1992) Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J Biol Chem 267:1430-1433.
144. Knudsen LB, Kiel D, Teng M, Behrens C, Bhumralkar D, Kodra JT, Holst JJ, Jeppesen CB, Johnson MD, and de Jong JC, et al. (2007) Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci USA 104:937-942.
145. Kojetin DJ and Burris TP (2014) REV-ERB and ROR nuclear receptors as drug targets. Nat Rev Drug Discov 13:197-216.
146. Kornev AP, Haste NM, Taylor SS, and Eyck LF (2006) Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci USA 103:17783-17788.
147. Koshland DE Jr, Némethy G, and Filmer D (1966) Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry 5:365-385.
148. Kostenis E and Mohr K (1996) Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. Trends Pharmacol Sci 17:280-283.
149. Krause RM, Buisson B, Bertrand S, Corringer PJ, Galzi JL, Changeux JP, and Bertrand D (1998) Ivermectin: a positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 53:283-294.
150. Kruse AC, Ring AM, Manglik A, Hu J, Hu K, Eitel K, Hübner H, Pardon E, Valant C, and Sexton PM, et al. (2013) Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504:101-106.
151. Kufareva I and Abagyan R (2008) Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. J Med Chem 51: 7921-7932.
152. Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, and Vaughn JP (2004) Development of Herceptin resistance in breast cancer cells. Cytometry A 57:86-93.
153. LaFrate AL, Gunther JR, Carlson KE, and Katzenellenbogen JA (2008) Synthesis and biological evaluation of guanylhydrazone coactivator binding inhibitors for the estrogen receptor. Bioorg Med Chem 16:10075-10084.
154. Landgraf KE, Santell L, Billeci KL, Quan C, Young JC, Maun HR, Kirchhofer D, and Lazarus RA (2010) Allosteric peptide activators of pro-hepatocyte growth factor stimulate Met signaling. J Biol Chem 285:40362-40372.
155. Lane JR, Sexton PM, and Christopoulos A (2013) Bridging the gap: bitopic ligands of G-protein-coupled receptors. Trends Pharmacol Sci 34:59-66.
156. Langmead CJ (2011) Determining allosteric modulator mechanism of action: integration of radioligand binding and functional assay data. Methods Mol Biol 746: 195-209.
157. Langmead CJ and Christopoulos A (2014) Functional and structural perspectives on allosteric modulation of GPCRs. Curr Opin Cell Biol 27:94-101.
158. Lanzafame AA, Sexton PM, and Christopoulos A (2006) Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors. Mol Pharmacol 70: 736-746.
159. Lazareno S, Dolezal V, Popham A, and Birdsall NJ (2004) Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol 65:257-266.
160. Lazareno S, Popham A, and Birdsall NJ (2002) Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. Mol Pharmacol 62:1492-1505.
161. Leach K, Loiacono RE, Felder CC, McKinzie DL, Mogg A, Shaw DB, Sexton PM, and Christopoulos A (2010) Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 35:855-869.
162. Leach K, Sexton PM, and Christopoulos A (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 28: 382-389.
163. Leach K, Wen A, Cook AE, Sexton PM, Conigrave AD, and Christopoulos A (2013) Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators. Endocrinology 154:1105-1116.
164. Leduc AM, Trent JO, Wittliff JL, Bramlett KS, Briggs SL, Chirgadze NY, Wang Y, Burris TP, and Spatola AF (2003) Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proc Natl Acad Sci USA 100: 11273-11278.
165. Lemmon MA and Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141:1117-1134.
166. Le Novère N, Grutter T, and Changeux JP (2002) Models of the extracellular domain of the nicotinic receptors and of agonist-and Ca2+-binding sites. Proc Natl Acad Sci USA 99:3210-3215.
167. Lewis M (2005) The lac repressor. C R Biol 328:521-548.
168. Lewis M, Chang G, Horton NC, Kercher MA, Pace HC, Schumacher MA, Brennan RG, and Lu P (1996) Crystal structure of the lactose operon repressor and its complexes with DNA and inducer. Science 271:1247-1254.
169. Levitzki A (2003) Protein kinase inhibitors as a therapeutic modality. Acc Chem Res 36:462-469.
170. Li B, Liu Y, Uno T, and Gray N (2004) Creating chemical diversity to target protein kinases. Comb Chem High Throughput Screen 7:453-472.
171. Li GD, Chiara DC, Cohen JB, and Olsen RW (2010) Numerous classes of general anesthetics inhibit etomidate binding to gamma-aminobutyric acid type A (GABAA) receptors. J Biol Chem 285:8615-8620.
172. Li GD, Chiara DC, Sawyer GW, Husain SS, Olsen RW, and Cohen JB (2006) Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog. J Neurosci 26:11599-11605.
173. Li-Smerin Y and Swartz KJ (1998) Gating modifier toxins reveal a conserved structural motif in voltage-gated Ca2+ and K+ channels. Proc Natl Acad Sci USA 95:8585-8589.
174. Liao M, Cao E, Julius D, and Cheng Y (2013) Structure of the TRPV1 ion channel determined by electron cryo-microscopy. Nature 504:107-112.
175. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, and Guo MD, et al. (2005) Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 16:800-807.
176. Lindsley CW, Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huff JR, and Huber HE, et al. (2005) Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett 15:761-764.
177. Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, Prézeau L, Pin JP, Thomsen C, and Kuhn R (1999) CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol 55:453-461.
178. Liu W, Chun E, Thompson AA, Chubukov P, Xu F, Katritch V, Han GW, Roth CB, Heitman LH, and IJzerman AP, et al. (2012) Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337:232-236.
179. Liu Y and Gray NS (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2:358-364.
180. Long SB, Tao X, Campbell EB, and MacKinnon R (2007) Atomic structure of a voltagedependent K+ channel in a lipid membrane-like environment. Nature 450: 376-382.
181. Lou X, Toresson G, Benod C, Suh JH, Philips KJ, Webb P, and Gustafsson JA (2014) Structure of the retinoid X receptor a-liver X receptor b (RXRa-LXRb) heterodimer on DNA. Nat Struct Mol Biol 21:277-281.
182. Lüllmann H, Ohnesorge FK, Schauwecker GC, and Wassermann O (1969) Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-bisammonium compounds. Eur J Pharmacol 6:241-247.
183. MacKinnon R and Miller C (1989) Mutant potassium channels with altered binding of charybdotoxin, a pore-blocking peptide inhibitor. Science 245:1382-1385.
184. Matulef K and Zagotta WN (2003) Cyclic nucleotide-gated ion channels. Annu Rev Cell Dev Biol 19:23-44.
185. May LT, Leach K, Sexton PM, and Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51.
186. Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, Conn PJ, and Lindsley CW (2012) Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem 55:1445-1464.
187. Mettu NB, Stanley TB, Dwyer MA, Jansen MS, Allen JE, Hall JM, and McDonnell DP (2007) The nuclear receptor-coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-activated receptors. Mol Endocrinol 21:2361-2377.
188. Mohr K, Schmitz J, Schrage R, Tränkle C, and Holzgrabe U (2013) Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors. Angew Chem Int Ed Engl 52:508-516.
189. Monod J, Changeux JP, and Jacob F (1963) Allosteric proteins and cellular control systems. J Mol Biol 6:306-329.
190. Monod J and Jacob F (1961) Teleonomic mechanisms in cellular metabolism, growth, and differentiation. Cold Spring Harb Symp Quant Biol 26:389-401.
191. Monod J, Wyman J, and Changeux JP (1965) On the nature of allosteric transitions: a plausible model. J Mol Biol 12:88-118.
192. Moore TW, Mayne CG, and Katzenellenbogen JA (2010) Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs). Mol Endocrinol 24:683-695.
193. Moras D and Gronemeyer H (1998) The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol 10:384-391.
194. Morgan DO (1996) The dynamics of cyclin dependent kinase structure. Curr Opin Cell Biol 8:767-772.
195. Mulle C, Léna C, and Changeux JP (1992) Potentiation of nicotinic receptor response by external calcium in rat central neurons. Neuron 8:937-945.
196. Nawaratne V, Leach K, Felder CC, Sexton PM, and Christopoulos A (2010) Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. J Biol Chem 285:19012-19021.
197. Nemecz A and Taylor P (2011) Creating an a7 nicotinic acetylcholine recognition domain from the acetylcholine-binding protein: crystallographic and ligand selectivity analyses. J Biol Chem 286:42555-42565.
198. Neubig RR, Spedding M, Kenakin T, and Christopoulos A; International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification (2003) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 55:597-606.
199. Nguyen NH, Apriletti JW, Cunha Lima ST, Webb P, Baxter JD, and Scanlan TS (2002) Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J Med Chem 45:3310-3320.
200. Nicholls DJ, Tomkinson NP, Wiley KE, Brammall A, Bowers L, Grahames C, Gaw A, Meghani P, Shelton P, and Wright TJ, et al. (2008) Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. Mol Pharmacol 74:1193-1202.
201. Niefind K, Raaf J, and Issinger OG (2009) Protein kinase CK2 in health and disease: Protein kinase CK2: from structures to insights. Cell Mol Life Sci 66:1800-1816.
202. Nilius B, Talavera K, Owsianik G, Prenen J, Droogmans G, and Voets T (2005) Gating of TRP channels: a voltage connection? J Physiol 567:35-44.
203. Noetzel MJ, Gregory KJ, Vinson PN, Manka JT, Stauffer SR, Lindsley CW, Niswender CM, Xiang Z, and Conn PJ (2013) A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling. Mol Pharmacol 83:835-847.
204. Nolen B, Taylor S, and Ghosh G (2004) Regulation of protein kinases; controlling activity through activation segment conformation. Mol Cell 15:661-675.
205. Norris JD, Paige LA, Christensen DJ, Chang CY, Huacani MR, Fan D, Hamilton PT, Fowlkes DM, and McDonnell DP (1999) Peptide antagonists of the human estrogen receptor. Science 285:744-746.
206. Nowycky MC, Fox AP, and Tsien RW (1985) Three types of neuronal calcium channel with different calcium agonist sensitivity. Nature 316:440-443.
207. Nury H, Van Renterghem C, Weng Y, Tran A, Baaden M, Dufresne V, Changeux JP, Sonner JM, Delarue M, and Corringer PJ (2011) X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel. Nature 469:428-431.
208. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McConnell P, Spessard C, and Banotai C, et al. (2004) Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 11:1192-1197.
209. Olivera BM, Miljanich GP, Ramachandran J, and Adams ME (1994) Calcium channel diversity and neurotransmitter release: the omega-conotoxins and omega-agatoxins. Annu Rev Biochem 63:823-867.
210. Olsen RW, Chang CS, Li G, Hanchar HJ, and Wallner M (2004) Fishing for allosteric sites on GABA(A) receptors. Biochem Pharmacol 68:1675-1684.
211. Olsen RW, Li GD, Wallner M, Trudell JR, Bertaccini EJ, Lindahl E, Miller KW, Alkana RL, and Davies DL (2014) Structural models of ligand-gated ion channels: sites of action for anesthetics and ethanol. Alcohol Clin Exp Res 38:595-603.
212. Olsen RW and Sapp DW (1995) Neuroactive steroid modulation of GABAA receptors. Adv Biochem Psychopharmacol 48:57-74.
213. Olsen RW and Sieghart W (2009) GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 56:141-148.
214. Orlov I, Rochel N, Moras D, and Klaholz BP (2012) Structure of the full human RXR/ VDR nuclear receptor heterodimer complex with its DR3 target DNA. EMBO J 31: 291-300.
215. Pan J, Chen Q, Willenbring D, Mowrey D, Kong XP, Cohen A, Divito CB, Xu Y, and Tang P (2012) Structure of the pentameric ligand-gated ion channel GLIC bound with anesthetic ketamine. Structure 20:1463-1469.
216. Pantazis A and Olcese R (2012) Relative transmembrane segment rearrangements during BK channel activation resolved by structurally assigned fluorophorequencher pairing. J Gen Physiol 140:207-218.
217. Parent AA, Gunther JR, and Katzenellenbogen JA (2008) Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med Chem 51:6512-6530.
218. Payandeh J, Gamal El-Din TM, Scheuer T, Zheng N, and Catterall WA (2012) Crystal structure of a voltage-gated sodium channel in two potentially inactivated states. Nature 486:135-139.
219. Payandeh J, Scheuer T, Zheng N, and Catterall WA (2011) The crystal structure of a voltage-gated sodium channel. Nature 475:353-358.
220. Perkins DI, Trudell JR, Crawford DK, Asatryan L, Alkana RL, and Davies DL (2009) Loop 2 structure in glycine and GABA(A) receptors plays a key role in determining ethanol sensitivity. J Biol Chem 284:27304-27314.
221. Peters JA, Cooper MA, Carland JE, Livesey MR, Hales TG, and Lambert JJ (2010) Novel structural determinants of single channel conductance and ion selectivity in 5-hydroxytryptamine type 3 and nicotinic acetylcholine receptors. J Physiol 588: 587-596.
222. Pike JW, Pathrose P, Barmina O, Chang CY, McDonnell DP, Yamamoto H, and Shevde NK (2003) Synthetic LXXLL peptide antagonize 1,25-dihydroxyvitamin D3-dependent transcription. J Cell Biochem 88:252-258.
223. Pin JP, Neubig R, Bouvier M, Devi L, Filizola M, Javitch JA, Lohse MJ, Milligan G, Palczewski K, and Parmentier M, et al. (2007) International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev 59:5-13.
224. Pin JP and Prézeau L (2007) Allosteric modulators of GABA(B) receptors: mechanism of action and therapeutic perspective. Curr Neuropharmacol 5:195-201.
225. Poon G (2005) Cinacalcet hydrochloride (Sensipar). Proc (Bayl Univ Med Cent) 18: 181-184.
226. Popovych N, Tzeng SR, Tonelli M, Ebright RH, and Kalodimos CG (2009) Structural basis for cAMP-mediated allosteric control of the catabolite activator protein. Proc Natl Acad Sci USA 106:6927-6932.
227. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A, McIntosh L, Goodwin G, and Walker G, et al. (2005) Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68:1484-1495.
228. Proska J and Tucek S (1994) Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors. Mol Pharmacol 45:709-717.
229. Ragsdale DS, McPhee JC, Scheuer T, and Catterall WA (1994) Molecular determinants of state-dependent block of Na+ channels by local anesthetics. Science 265: 1724-1728.
230. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, and Calinski D, et al. (2011) Crystal structure of the b2 adrenergic receptor-Gs protein complex. Nature 477:549-555.
231. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, and Moras D (1995) Crystal structure of the RAR-gamma ligand-binding domain bound to alltrans retinoic acid. Nature 378:681-689.
232. Revah F, Bertrand D, Galzi JL, Devillers-Thiéry A, Mulle C, Hussy N, Bertrand S, Ballivet M, and Changeux JP (1991) Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor. Nature 353:846-849.
233. Roell MK, Issafras H, Bauer RJ, Michelson KS, Mendoza N, Vanegas SI, Gross LM, Larsen PD, Bedinger DH, and Bohmann DJ, et al. (2010) Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity. J Biol Chem 285:20607-20614.
234. Rogers CJ, Twyman RE, and Macdonald RL (1994) Benzodiazepine and betacarboline regulation of single GABAA receptor channels of mouse spinal neurones in culture. J Physiol 475:69-82.
235. Rubin MM and Changeux JP (1966) On the nature of allosteric transitions: implications of non-exclusive ligand binding. J Mol Biol 21:265-274.
236. SandersMJ, Ali ZS, Hegarty BD, Heath R, SnowdenMA, and Carling D (2007) Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem 282:32539-32548.
237. Sauguet L, Howard RJ, Malherbe L, Lee US, Corringer PJ, Harris RA, and Delarue M (2013) Structural basis for potentiation by alcohols and anaesthetics in a ligandgated ion channel. Nat Commun 4:1697.
238. Sauguet L, Shahsavar A, Poitevin F, Huon C, Menny A, Nemecz À, Haouz A, Changeux JP, Corringer PJ, and Delarue M (2014) Crystal structures of a pentameric ligand-gated ion channel provide a mechanism for activation. Proc Natl Acad Sci USA 111:966-971.
239. Savkur RS and Burris TP (2004) The coactivator LXXLL nuclear receptor recognition motif. J Pept Res 63:207-212.
240. Sawyer GW, Chiara DC, Olsen RW, and Cohen JB (2002) Identification of the bovine gamma-aminobutyric acid type A receptor alpha subunit residues photolabeled by the imidazobenzodiazepine [3H]Ro15-4513. J Biol Chem 277:50036-50045.
241. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, and Hasmann M (2009) Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69: 9330-9336.
242. Schmalhofer WA, Calhoun J, Burrows R, Bailey T, Kohler MG, Weinglass AB, Kaczorowski GJ, Garcia ML, Koltzenburg M, and Priest BT (2008) ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors. Mol Pharmacol 74:1476-1484.
243. Scholten DJ, Canals M, Maussang D, Roumen L, Smit MJ, Wijtmans M, de Graaf C, Vischer HF, and Leurs R (2012) Pharmacological modulation of chemokine receptor function. Br J Pharmacol 165:1617-1643.
244. Sinnegger MJ, Wang Z, Grabner M, Hering S, Striessnig J, Glossmann H, and Mitterdorfer J (1997) Nine L-type amino acid residues confer full 1,4-dihydropyridine sensitivity to the neuronal calcium channel alpha1A subunit. Role of L-type Met1188. J Biol Chem 272:27686-27693.
245. Smith GB and Olsen RW (1995) Functional domains of GABAA receptors. Trends Pharmacol Sci 16:162-168.
246. Smith GB and Olsen RW (2000) Deduction of amino acid residues in the GABA(A) receptor alpha subunits photoaffinity labeled with the benzodiazepine flunitrazepam. Neuropharmacology 39:55-64.
247. Sokolov S, Kraus RL, Scheuer T, and Catterall WA (2008) Inhibition of sodium channel gating by trapping the domain II voltage sensor with protoxin II. Mol Pharmacol 73:1020-1028.
248. Srinivasan S, Nwachukwu JC, Parent AA, Cavett V, Nowak J, Hughes TS, Kojetin DJ, Katzenellenbogen JA, and Nettles KW (2013) Ligand-binding dynamics rewire cellular signaling via estrogen receptor-a. Nat Chem Biol 9:326-332.
249. Spedding M (1985a) Activators and inactivators of Ca++ channels: new perspectives. J Pharmacol 16:319-343.
250. 2+? Naunyn Schmiedebergs Arch Pharmacol 328:464-466.
251. Spedding M, Kenny B, and Chatelain P (1995) New drug binding sites in Ca2+ channels. Trends Pharmacol Sci 16:139-142.
252. Spedding M and Mir AK (1987) Direct activation of Ca2+ channels by palmitoyl carnitine, a putative endogenous ligand. Br J Pharmacol 92:457-468.
253. Spedding M and Paoletti R (1992) Classification of calcium channels and the sites of action of drugs modifying channel function. Pharmacol Rev 44:363-376.
254. Steinfeld T, Mammen M, Smith JA, Wilson RD, and Jasper JR (2007) A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol Pharmacol 72:291-302.
255. Stephenson RP (1956) A modification of receptor theory. Br Pharmacol Chemother 11:379-393.
256. Stockton JM, Birdsall NJ, Burgen AS, and Hulme EC (1983)Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 23:551-557.
257. Striessnig J (1999) Pharmacology, structure and function of cardiac L-type Ca(2+) channels. Cell Physiol Biochem 9:242-269.
258. Study RE and Barker JL (1981) Diazepam and (-)-pentobarbital: fluctuation analysis reveals different mechanisms for potentiation of gamma-aminobutyric acid responses in cultured central neurons. Proc Natl Acad Sci USA 78: 7180-7184.
259. Taly A, Corringer PJ, Grutter T, Prado de Carvalho L, Karplus M, and Changeux JP (2006) Implications of the quaternary twist allosteric model for the physiology and pathology of nicotinic acetylcholine receptors. Proc Natl Acad Sci USA 103: 16965-16970.
260. Taly A, Corringer PJ, Guedin D, Lestage P, and Changeux JP (2009) Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov 8:733-750.
261. Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I, Li T, Ma L, Fenalti G, and Li J, et al. (2013) Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341:1387-1390.
262. Tao YX (2008) Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics. Pharmacol Ther 120: 129-148.
263. Taylor SS and Kornev AP (2011) Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci 36:65-77.
264. Thron CD (1973) On the analysis of pharmacological experiments in terms of an allosteric receptor model. Mol Pharmacol 9:1-9.
265. Tikhonov DB and Zhorov BS (2012) Architecture and pore block of eukaryotic voltage-gated sodium channels in view of NavAb bacterial sodium channel structure. Mol Pharmacol 82:97-104.
266. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, and Rosenfeld MG (1997) The transcriptional co-activator p/CIP binds CBP and mediates nuclearreceptor function. Nature 387:677-684.
267. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, and Dingledine R (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62:405-496.
268. Tummino PJ and Copeland RA (2008) Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47:5481-5492.
269. Udugamasooriya DG, Dineen SP, Brekken RA, and Kodadek T (2008) A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity. J Am Chem Soc 130:5744-5752.
270. Valant C, Felder CC, Sexton PM, and Christopoulos A (2012a) Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects. Mol Pharmacol 81:41-52.
271. Valant C, Gregory KJ, Hall NE, Scammells PJ, Lew MJ, Sexton PM, and Christopoulos A (2008) A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J Biol Chem 283:29312-29321.
272. Valant C, Robert Lane J, Sexton PM, and Christopoulos A (2012b) The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. Annu Rev Pharmacol Toxicol 52:153-178.
273. Vanderpool D, Johnson TO, Ping C, Bergqvist S, Alton G, Phonephaly S, Rui E, Luo C, Deng YL, and Grant S, et al. (2009) Characterization of the CHK1 allosteric inhibitor binding site. Biochemistry 48:9823-9830.
274. Van Giezen JJJ, Nilsson L, Berntsson P, Wissing B-M, Giordanetto F, Tomlinson W, and Greasley PJ (2009) Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 7:1556-1565.
275. Vargas E, Yarov-Yarovoy V, Khalili-Araghi F, Catterall WA, Klein ML, Tarek M, Lindahl E, Schulten K, Perozo E, and Bezanilla F, et al. (2012) An emerging consensus on voltage-dependent gating from computational modeling and molecular dynamics simulations. J Gen Physiol 140:587-594.
276. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, and Babu MM (2013) Molecular signatures of G-protein-coupled receptors. Nature 494:185-194.
277. Vernino S, Amador M, Luetje CW, Patrick J, and Dani JA (1992) Calcium modulation and high calcium permeability of neuronal nicotinic acetylcholine receptors. Neuron 8:127-134.
278. Vieth M, Higgs RE, Robertson DH, Shapiro M, Gragg EA, and Hemmerle H (2004) Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim Biophys Acta 1697:243-257.
279. Vieth M, Sutherland JJ, Robertson DH, and Campbell RM (2005) Kinomics: characterizing the therapeutically validated kinase space. Drug Discov Today 10:839-846.
280. Voegel JJ, Heine MJ, Tini M, Vivat V, Chambon P, and Gronemeyer H (1998) The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and-independent pathways. EMBO J 17:507-519.
281. Wang X and Sun SY (2009) Enhancing mTOR-targeted cancer therapy. Expert Opin Ther Targets 13:1193-1203.
282. Wang Y, Chirgadze NY, Briggs SL, Khan S, Jensen EV, and Burris TP (2006) A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor beta. Proc Natl Acad Sci USA 103:9908-9911.
283. Weng Y, Yang L, Corringer PJ, and Sonner JM (2010) Anesthetic sensitivity of the Gloeobacter violaceus proton-gated ion channel. Anesth Analg 110:59-63.
284. Winterfield JR and Swartz KJ (2000) A hot spot for the interaction of gating modifier toxins with voltage-dependent ion channels. J Gen Physiol 116:637-644.
285. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, and Lackey K, et al. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64:6652-6659.
286. Wootten D, Christopoulos A, and Sexton PM (2013) Emerging paradigms in GPCR allostery: implications for drug discovery. Nat Rev Drug Discov 12:630-644.
287. Wootten D, Simms J, Koole C, Woodman OL, Summers RJ, Christopoulos A, and Sexton PM (2011) Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids. J Pharmacol Exp Ther 336:540-550.
288. Wu H, Wang C, Gregory KJ, Han GW, Cho HP, Xia Y, Niswender CM, Katritch V, Meiler J, and Cherezov V, et al. (2014) Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science 344:58-64.
289. Wu LJ, Sweet TB, and Clapham DE (2010a) International Union of Basic and Clinical Pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family. Pharmacol Rev 62:381-404.
290. Wu Y, Yang Y, Ye S, and Jiang Y (2010b) Structure of the gating ring from the human large-conductance Ca(2+)-gated K(+) channel. Nature 466:393-397.
291. Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, and Pavletich NP (2013) mTOR kinase structure, mechanism and regulation. Nature 497:217-223.
292. Yarov-Yarovoy V, DeCaen PG, Westenbroek RE, Pan CY, Scheuer T, Baker D, and Catterall WA (2012) Structural basis for gating charge movement in the voltage sensor of a sodium channel. Proc Natl Acad Sci USA 109:E93-E102.
293. Yu FH and Catterall WA (2004) The VGL-chanome: a protein superfamily specialized for electrical signaling and ionic homeostasis. Sci STKE 2004:re15.
294. Yu Z, Klaasse E, Heitman LH, and Ijzerman AP (2014) Allosteric modulators of the hERG K(+) channel: radioligand binding assays reveal allosteric characteristics of dofetilide analogs. Toxicol Appl Pharmacol 274:78-86.
295. Yuan P, Leonetti MD, Pico AR, Hsiung Y, and MacKinnon R (2010) Structure of the human BK channel Ca2+-activation apparatus at 3.0 A resolution. Science 329: 182-186.
296. Zhang J, Adrián FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, Sim T, Powers J, Dierks C, and Sun F, et al. (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463:501-506.
297. Zhang J, Yang PL, and Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9:28-39.
298. Zhang X, Gureasko J, Shen K, Cole PA, and Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125:1137-1149.
299. Zhang X, Ren W, DeCaen P, Yan C, Tao X, Tang L, Wang J, Hasegawa K, Kumasaka T, and He J, et al. (2012) Crystal structure of an orthologue of the NaChBac voltage-gated sodium channel. Nature 486:130-134.
300. Zimmermann I, Marabelli A, Bertozzi C, Sivilotti LG, and Dutzler R (2012) Inhibition of the prokaryotic pentameric ligand-gated ion channel ELIC by divalent cations. PLoS Biol 10:e1001429.
301. Zuccotto F, Ardini E, Casale E, and Angiolini M (2010) Through the "gatekeeper door": exploiting the active kinase conformation. J Med Chem 53:2681-2694.
302. Zweemer AJ, Nederpelt I, Vrieling H, Hafith S, Doornbos ML, de Vries H, Abt J, Gross R, Stamos D, and Saunders J, et al. (2013) Multiple binding sites for smallmolecule antagonists at the CC chemokine receptor 2. Mol Pharmacol 84:551-561.